



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/103594/2024

European Medicines Agency decision P/0082/2024

of 15 March 2024

on the agreement of a paediatric investigation plan and on the granting of a deferral for navepegritide (EMA-002689-PIP02-23) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0082/2024

of 15 March 2024

on the agreement of a paediatric investigation plan and on the granting of a deferral for navepegritide (EMA-002689-PIP02-23) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the application submitted by Ascendis Pharma Growth Disorders A/S on 19 April 2023 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 23 February 2024, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

A paediatric investigation plan for navepegritide, powder and solvent for solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for navepegritide, powder and solvent for solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Ascendis Pharma Growth Disorders A/S, Tuborg Boulevard 12, 2900 – Hellerup, Denmark.

EMA/PDCO/541364/2023
Amsterdam, 23 February 2024

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral

EMA-002689-PIP02-23

Scope of the application

Active substance(s):

Navepegritide

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of achondroplasia

Pharmaceutical form(s):

Powder and solvent for solution for injection

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

Ascendis Pharma Growth Disorders A/S

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Ascendis Pharma Growth Disorders A/S submitted for agreement to the European Medicines Agency on 19 April 2023 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation.

The procedure started on 22 May 2023.

Supplementary information was provided by the applicant on 11 November 2023.

The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable

2. Paediatric investigation plan

2.1. Condition:

Treatment of achondroplasia

2.1.1. Indication(s) targeted by the PIP

Treatment of achondroplasia

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Powder and solvent for solution for injection

2.1.4. Measures

Area	Description
Quality-related studies	Not applicable
Non-clinical studies	Not applicable
Clinical studies	Study 1 (TCC-NHS-01) Multicentre, observational study to collect specific growth measurements in children with achondroplasia from birth to less than 9 years of age Study 2 (TCC-201) Double-blind, randomised, placebo-controlled, dose-escalation trial to evaluate pharmacokinetics, safety and efficacy of navepegritide in children with achondroplasia from 2 years to less than 11 years of age Study 3 (ASND0036) Double-blind, randomised, placebo-controlled, multicentre trial to evaluate safety and efficacy of navepegritide in children with achondroplasia from 2 to less than 12 years of age Study 4 (ASND0039) Multicentre, open-label, long-term extension trial to evaluate tolerability, safety and efficacy of navepegritide in children with achondroplasia from 2 years to less than 18 years of age

	Study 5 (ASND0030) Double-blind, randomised, placebo-controlled, multicentre, trial to evaluate safety, tolerability and efficacy of navepegritide in children with achondroplasia from birth to less than 2 years of age Study 6 (ASND0045) Double-blind, randomised, placebo-controlled, multicentre trial to evaluate safety, tolerability and efficacy of navepegritide in children with achondroplasia and open growth plates from 12 years to less than 18 years of age Study 7 (ASND0041) Open-label, randomised, 3-treatment, 6-sequence, 3-period crossover trial in healthy adult participants to compare the relative bioavailability of the navepegritide formulation used in Phase 2 trials versus the to-be-marketed drug product (DP) presentations
Modelling and simulation analyses	Study 8 Population pharmacokinetic study to confirm or modify the paediatric posology compared to the regimen used in clinical trials in children from 2 to less than 18 years of age Study 9 Population pharmacokinetic study to confirm or modify the paediatric posology compared to the regimen used in clinical trials in children from birth to less than 2 years of age Study 10 Population pharmacokinetic study to confirm or modify the paediatric posology compared to the regimen used in clinical trials in children from 12 to less than 18 years of age
Other studies	Not applicable
Extrapolation plan	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By August 2034
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

The product is not authorised anywhere in the European Community.